What is the recommended dosage of domperidone (antiemetic/prokinetic agent) for pediatric patients?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: December 15, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Domperidone Dosing in Pediatric Patients

The recommended pediatric dosage of domperidone is 0.2-0.3 mg/kg three times daily (before meals), with a maximum daily dose not exceeding 30 mg/day and treatment duration limited to less than 7 days due to cardiac safety concerns. 1, 2

Standard Dosing Regimens

Age-Based Recommendations

  • Infants: 0.2 mg/kg three times daily (before meals) 1
  • Children 1 month to 12.7 years: 2 mg/kg/day divided into four doses daily 1
  • Alternative dosing: 0.3 mg/kg three times daily has been used effectively in clinical trials 3

Maximum Dose Limitations

  • Daily maximum: Do not exceed 30 mg/day total dose 2
  • Duration: Limit continuous use to less than 7 days 2
  • These restrictions were implemented following 2014 safety warnings regarding cardiac adverse effects in children 2

Clinical Context and Safety Considerations

Regulatory Status and Off-Label Use

  • Domperidone is currently authorized only for nausea and vomiting in children older than 12 years for short-term use 4
  • Pediatric gastroenterologists commonly prescribe it off-label for gastroesophageal reflux disease, dyspepsia, and gastroparesis 4
  • Critical caveat: After the 2014 safety warning, prescribing patterns appropriately shifted toward lower doses, shorter durations, and fewer drug interactions 2

Evidence Quality

  • The highest quality pediatric dosing evidence comes from a 2006 uncontrolled study showing 64.5% improvement in infants at 0.2 mg/kg three times daily and 100% improvement in older children at 2 mg/kg/day divided four times daily 1
  • A 1979 double-blind trial demonstrated that 0.3 mg/kg three times daily was significantly more effective than both metoclopramide and placebo for chronic vomiting and regurgitation 3
  • Important limitation: No recent high-quality controlled trials exist to support domperidone efficacy in pediatric patients 1

Administration Guidelines

  • Timing: Administer before meals (three times daily dosing) 3
  • Formulation: Available as 1% drops for easier administration in infants and young children 3
  • Intravenous use: If given IV (primarily in oncology settings), use 0.7 mg/kg per dose with adequate dilution to prevent injection site pain 5

Drug Interactions and Contraindications

  • Following the 2014 safety warning, co-prescription of medications that interact with domperidone significantly decreased 2
  • Avoid concurrent use with drugs that prolong QT interval or inhibit CYP3A4 metabolism 2
  • Monitor for cardiac arrhythmias, particularly in patients with underlying cardiac conditions 2

Adverse Effects Profile

  • Domperidone has a better tolerability profile than metoclopramide in pediatric populations 3
  • Plasma prolactin elevation occurs in all patients but prolactin-related adverse events are observed in only 10-20% 6
  • Pain at IV injection site can occur if inadequately diluted 5

References

Guideline

Pediatric Dosing for Domperidone

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Research

Domperidone prescribing patterns in pediatric patients before and after safety warning in South Korea.

International journal of clinical pharmacology and therapeutics, 2020

Research

Drugs in Focus: Domperidone.

Journal of pediatric gastroenterology and nutrition, 2023

Research

Domperidone as an antiemetic in paediatric oncology.

Cancer chemotherapy and pharmacology, 1981

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.